deltatrials
Terminated PHASE2 NCT00418782

A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain

A 2 Week, Randomized, Double Blind, Placebo And Positive Controlled, Parallel Group, Multicenter Study Of CE-224,535 In Subjects With Osteoarthritic Pain Of The Knee

Sponsor: Pfizer

Conditions Osteoarthritis
Interventions CE-224535 naproxen placebo
Updated 7 times since 2017 Last updated: Dec 3, 2018 Started: Jan 31, 2007 Completion: Aug 31, 2007

This PHASE2 trial investigates Osteoarthritis and is currently terminated or withdrawn. Pfizer leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2019 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2019 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anniston, United States, Arlington, United States, Ashland, United States, Avon, United States, Baltimore, United States, Bayou La Batre, United States, Beavercreek, United States, Birmingham, United States, Bryan, United States, Chicago, United States and 32 more location s